Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>MariMed reported 4Q revenue of $38.9 million, which was exactly in line with our estimate.</li><li>This represents a 0.26% increase Q/Q and an 8.66% improvement Y/Y. Gross margins were 44.47%, a gain of 1.80% sequentially and 0.34% Y/Y.</li><li>Revenue was helped by a full contribution from the Thrive Dispensary in Casey, Illinois and beginning operations at the Mt. Vernon, Illinois manufacturing facility. </li></ul>

MariMed reported 4Q revenue of $38.9 million, which was exactly in line with our estimate.This represents a 0.26% increase Q/Q and an 8.66% improvement Y/Y. Gross margins were 44.47%, a gain of 1.80% sequentially and 0.34% Y/Y.Revenue was helped by a full contribution from the Thrive Dispensary in Casey, Illinois and beginning operations at the Mt. Vernon, Illinois manufacturing facility. 

MariMed, Inc. - Poised for Growth in 2024

<ul><li>MariMed has begun manufacturing and processing cannabis products in its new kitchen in Mount Vernon, Illinois.</li><li>As often happens in cannabis, there were construction and regulatory delays, but the company expects to have its award-winning edibles in Illinois stores in time for the holidays.</li><li>Illinois is the sixth-most populated state with 12.7 million residents.</li></ul>

MariMed has begun manufacturing and processing cannabis products in its new kitchen in Mount Vernon, Illinois.As often happens in cannabis, there were construction and regulatory delays, but the company expects to have its award-winning edibles in Illinois stores in time for the holidays.Illinois is the sixth-most populated state with 12.7 million residents.

MariMed, Inc. - Begins Manufacturing and Processing in Illinois

<ul><li>MariMed closed a $58.7 million secured credit facility with a US chartered bank on November 17, 2023.</li><li>The refinancing will result in a $4.7 million reduction to principal and interest expense in the first 12 months and $3.5 million annually for the next four years.</li><li>MariMed estimates its new weighted average cost of debt is now about 8%, down from more than 11% previously.</li></ul>

MariMed closed a $58.7 million secured credit facility with a US chartered bank on November 17, 2023.The refinancing will result in a $4.7 million reduction to principal and interest expense in the first 12 months and $3.5 million annually for the next four years.MariMed estimates its new weighted average cost of debt is now about 8%, down from more than 11% previously.

MariMed, Inc. - Closes $58.7 Million Debt Refinancing

<ul><li>MariMed report 3Q revenue of $38.8 million, which was slightly ahead of our estimate of $38.5 million.</li><li>This represents a 6.3% increase Q/Q and a 14.4% improvement Y/Y.</li><li>The revenue increase was driven primarily by Maryland. MariMed has a dispensary in Annapolis that converted to adult-use on July 1 and sales grew 88% Q/Q. </li></ul>

MariMed report 3Q revenue of $38.8 million, which was slightly ahead of our estimate of $38.5 million.This represents a 6.3% increase Q/Q and a 14.4% improvement Y/Y.The revenue increase was driven primarily by Maryland. MariMed has a dispensary in Annapolis that converted to adult-use on July 1 and sales grew 88% Q/Q. 

MariMed, Inc. - 3Q23 Revenue Exceeds Estimates; Adjusted EBITDA In Line

<ul><li>MariMed reports 3Q earnings on November 8 after the close.</li><li>Q/Q, we are expecting 5.4% revenue growth and a slight contraction in AEBITDA.</li><li>Maryland should be the most significant driver of the top-line improvement.</li></ul>

MariMed reports 3Q earnings on November 8 after the close.Q/Q, we are expecting 5.4% revenue growth and a slight contraction in AEBITDA.Maryland should be the most significant driver of the top-line improvement.

United States

MariMed, Inc. operates as a pharmaceutical company. The Company specializes in designing, development, operation, funding, and optimization of medical cannabis cultivation, production centers, and dispensaries. MariMed serves customers in the State of Massachusetts.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MariMed (MRMD US)

MariMed, Inc. - Poised for Growth in 2024

Revenue was helped by a full contribution from the Thrive Dispensary in Casey, Illinois and beginning operations at the Mt. Vernon, Illinois...

Water Tower Research

MariMed, Inc. - Begins Manufacturing and Processing in Illinois

As often happens in cannabis, there were construction and regulatory delays, but the company expects to have its award-winning edibles in Illinois...

Water Tower Research

MariMed, Inc. - Closes $58.7 Million Debt Refinancing

The refinancing will result in a $4.7 million reduction to principal and interest expense in the first 12 months and $3.5 million annually for the...

Water Tower Research

MariMed, Inc. - 3Q23 Revenue Exceeds Estimates; Adjusted EBITDA In Line

MariMed report 3Q revenue of $38.8 million, which was slightly ahead of our estimate of $38.5 million. This represents a 6.3% increase Q/Q and a...

Water Tower Research

MariMed, Inc. - 3Q Earnings Preview

MariMed reports 3Q earnings on November 8 after the close. Q/Q, we are expecting 5.4% revenue growth and a slight contraction in AEBITDA.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)